RT Journal Article
SR Electronic
T1 A rapid review of equity considerations in large-scale testing campaigns during infectious disease epidemics
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.02.22.21252205
DO 10.1101/2021.02.22.21252205
A1 Ost, Katarina
A1 Duquesne, Louise
A1 Duguay, Claudia
A1 Traverson, Lola
A1 Mathevet, Isadora
A1 Ridde, Valéry
A1 Zinszer, Kate
YR 2021
UL http://medrxiv.org/content/early/2021/03/03/2021.02.22.21252205.abstract
AB Context Large-scale testing is an intervention that is instrumental for infectious disease control and a central tool for the COVID-19 pandemic. Our rapid review aimed to identify if and how equity has been considered in large-scale testing initiatives.Methods We searched Web of Science and PubMed in November 2020 and followed PRISMA recommendations for scoping reviews. Articles were analyzed using descriptive and thematic analysis.Results Our search resulted in 291 studies of which 41 were included for data extraction after full article screening. Most of the included articles (83%) reported on HIV-related screening programs, while the remaining programs focused on other sexually transmitted infections (n=3) or COVID-19 (n=4). None of the studies presented a formal definition of (in)equity in testing, however, 23 articles did indirectly include elements of equity in the program or intervention design, largely through the justification of their target population.Conclusion The studies included in our rapid review did not explicitly consider equity in their design or evaluation. It is imperative that equity is incorporated into the design of infectious disease testing programs and serves as an important reminder of how equity considerations are needed for SARS-CoV-2 testing and vaccination programs.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by The Fonds de recherche du Quebec: Sante (FRQS) [ZINKA170, 2020]; CIHR Canadian 2019 Novel Coronavirus Rapid Research Competition [440254]; and the French National Research Agency (ANR) (ANR-20-COVI-000). Authors have no conflicts of interest to declare.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Rapid review of peer-reviewed literature, no IRB approval required.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll rapid review search criteria, databases, and keywords are listed in the manuscript or appendix.